[1]张燕枝,彭惠.干性年龄相关性黄斑变性治疗的研究进展[J].眼科新进展,2017,37(4):379-383.[doi:10.13389/j.cnki.rao.2017.0097]
　ZHANG Yan-Zhi,PENG Hui.Research advances in therapy of dry age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(4):379-383.[doi:10.13389/j.cnki.rao.2017.0097]
点击复制

干性年龄相关性黄斑变性治疗的研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年4期
页码:
379-383
栏目:
文献综述
出版日期:
2017-04-05

文章信息/Info

Title:
Research advances in therapy of dry age-related macular degeneration
作者:
张燕枝; 彭惠
400016　重庆市，重庆医科大学附属第一医院，眼科学重庆重点实验室，重庆市眼科研究所
Author(s):
ZHANG Yan-Zhi; PENG Hui
First Affiliated Hospital of Chongqing Medical University，Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute，Chongqing 400016，China
关键词:
干性年龄相关性黄斑变性; 氧化应激; 脂褐质; 玻璃膜疣; 睫状神经营养因子; 纳米二氧化铈; 人单克隆抗体; 光感受器移植
Keywords:
dry age-related macular degeneration; oxidative stress; lipofuscin; drusen;  ciliary neurotrophic factor; nanoceria; human monoclonal antibody; photoreceptor transplantation
分类号:
R777.2
DOI:
10.13389/j.cnki.rao.2017.0097
文献标志码:
A
摘要:
年龄相关性黄斑变性（age-related macular degeneration，AMD）是60岁以上老年人视力不可逆性损伤的首要原因，其发病率随着年龄的增加而增高。干性AMD是AMD最常见的一种类型，它会引起视力逐渐下降，病情进展非常缓慢，干性AMD病程发展到晚期时，出现地图样萎缩，中心视力也会缺失。目前普遍认为其发病机制主要由慢性炎症损伤、氧化应激损伤、脂褐质沉积及玻璃膜疣形成、脉络膜血供不足等引起，针对病因治疗是当前主要治疗方案，但一些新的治疗方法如番红花酸、姜黄色素、睫状神经营养因子、纳米二氧化铈和人单克隆抗体、光感受器及干细胞移植等目前均用于治疗干性AMD。本文就干性AMD治疗的研究进展进行综述。
Abstract:
Age-related macular degeneration(AMD) is the major cause of irreversible damage to vision in over 60 years old.Its incidence is increasing with age.Dry AMD is one of the most common types,causing the loss of vision is very slow.At the late stage,the geographic atrophy will be found,in which central vision is severely lost.It is widely believed that chronic inflammantion injury,oxidative stress injury,lipofuscin,drusen and choroid ischemia are the major pathogenesis.Now,the treatment is major aiming to the pathogenesis.But some new therapies such as crocetin,curcumin,ciliary neurotrophic factor,nanoceria,human monoclonal antibody,photoreceptor and stem cell transplantation have some efficiency to dry AMD.This article reviews the research advances in therapy of dry AMD.

参考文献/References:

［1］　MILLER JW.Age-related macular degeneration revisited-piecing the puzzle：the LXIX Edward Jackson memorial lecture［J］.Am J Ophthalmol，2013，155(1)：1-35.
［2］　GEHRS KM，JACKSON JR，BROWN EN，ALLIKMETS R，HAGEMAN GS.Complement，age-related macular degeneration and a vision of the future［J］.Arch Ophthalmol，2010，128(3)：349-358.
［3］　CHEREPANOFF S，MCMENAMIN P，GILLIES MC，KETTLE E，SARKS SH.Bruch’s membrane and choroidal macrophages in early and advanced age-related macular degeneration［J］.Br J Ophthalmol，2010，94(7)：918-925.
［4］　CAI X，MCGINNIS JF.Nanoceria：a potential therapeutic for dry AMD［J］.Adv Exp Med Biol，2016，854：111-118.
［5］　ZOHAR Y，PORTELLA NR，GIOVANNI G，PENHA FM，MOSHFEGHI AA，ZHANG K，et al.Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration：the complete study［J］.Ophthalmology，2013，121(3)：693-701.
［6］　WONG WT，DRESNER S，FOROOGHIAN F，GLASER T，DOSS L，ZHOU M，et al.Treatment of geographic atrophy with subconjunctival sirolimus：results of a phase I/II clinical trial［J］.Invest Ophthalmol Vis Sci，2013，54(4)：2941-2950.
［7］　QUERQUES G，ROSENFELD PJ，CAVALLERO E，BORRELLI E，CORVI F，QUERQUES L，et al.Treatment of dry age-related macular degeneration［J］.Ophthalmic Res，2014，52(3)：107-115.
［8］　OHNO-MATSUI K.Parallel findings in age-related macular degeneration and Alzheimer’s disease［J］.Prog Retin Eye Res，2011，30(4)：217-238.
［9］　DING JD，JOHNSON LV，HERRMANN R，FARSIU S，SMITH SG，GROELLE M，et al.Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration［J］.Proc Natl Acad Sci USA，2011，108(28)：279-287.
［10］　CATCHPOLE I，GERMASCHEWSKI V，KAM JH，LEITHNER PLV，FORD S，GOUGH G，et al.Systemic administration of A-beta mAb reduces retinal deposition of A-beta and activated complement C3 in age-related macular degeneration mouse model［J］.PLoS One，2013，8(6)：e65518.
［11］　BUSCHINI E，FEA AM，LAVIA CA，NASSISI M，PIGNATA G，ZOLA M，et al.Recent developments in the management of dry age-related macular degeneration［J］.Clin Ophthalmol，2015，9：563-574.
［12］　LANDA G，ROSEN RB，PATEL A，LIMA VC，TAI KW，PEREZ VR，et al.Qualitative spectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone［J］.J Ocul Pharmacol Ther，2011，27(1)：77-82.
［13］　VISHWANATHAN R，CHUNG M，JOHNSON EJ.A systematic review on zinc for the prevention and treatment of age-related macular degeneration［J］.Invest Ophthalmol Vis Sci，2013，54(6)：3985-3998.
［14］　SIN HPY，LIU DTL，LAM DSC.Lifestyle modification，nutritional and vitamins supplements for age-related macular degeneration［J］.Acta Ophthalmol，2012，91(1)：6-11.
［15］　CHONG WT，WONG TY，KREIS AJ，SIMPSON JA，GUYMER RH.Dietary antioxidants and primary prevention of age related macular degeneration：systematic review and meta-analysis［J］.BMJ，2007，335(7623)：755.
［16］　CHONG EW，KREIS AJ，WONG TY，SIMPSON JA，GUYMER RH.Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration：a systematic review and meta-analysis［J］.Arch Ophthalmol，2008，126(6)：826-833.
［17］　FALSINI B，PICCARDI M，MINNELLA A，SAVASTANO C，CAPOLUONGO E，FADDA A，et al.Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration［J］.Invest Ophthalmol Vis Sci，2010，51(12)：6118-6124.
［18］　CHANG YC，CHANG WC，HUNG KH，YANG DM，CHENG YH，LIAO YW，et al.The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform：identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress［J］.Front Aging Neurosci，2014，6(8)：191.
［19］　NAGINENI CN，RAJU R，NAGINENI KK，KOMMINENI VK，CHERUKURI A，KRISHNAN RK，et al.Resveratrol suppresses expression of VEGF by human retinal pigment epithelial cells：potential nutraceu tical for age-related macular degeneration［J］.Aging Dis，2014，5(2)：88-100.
［20］　ZHANG K，HOPKINS JJ，HEIER JS，BIRCH DG，HALPERIN LS，ALBINI TA，et al.Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration［J］.Proc Natl Acad Sci USA，2011，108(15)：6241-6245.
［21］　LI Y，TAO W，LUO L，HUANG D，KAUPER K，STABILA P，et al.CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration［J］.PLoS One，2010，5(3)：e9495.
［22］　MATA NL，LICHTER JB，VOGEL R，HAN Y，BUI TV，SINGERMAN LJ.Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration［J］.Retina，2012，33(3)：498-507.
［23］　HOLZ FG，STRAUSS EC，SCHMITZ-VALCKENBERG S，CAMPAGNE MVL.Geographic atrophy：clinical features and potential therapeutic approaches［J］.Ophthalmology，2014，121(5)：1079-1091.
［24］　GRUNWALD JE，METELITSINA TI，DUPONT JC，YING GS，MAGUIRE MG.Reduced foveolar choroidal blood flow in eyes with increasing AMD severity［J］.Invest Ophthalmol Vis Sci，2005，46(3)：1033-1038.
［25］　BOLTZ A，LUKSCH A，WIMPISSINGER B，MAAR N，WEIGERT G，FRANTAL S，et al.Choroidal blood flow and progression of agerelated macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization［J］.Invest Ophthalmol Vis Sci，2010，51(8)：4220-4225.
［26］　RALSTON PG，SLOAN D，WATERS-HONCU D，SAIGAL S，TORKILDSEN G.Apilot，open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration［J］.Invest Ophthalmol Vis Sci，2010，51(13)：913.
［27］　PEMP B，GARHOFER G，LASTA M，SCHMIDL D，WOLZT M，SCHMETTERER L.The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects［J］.Acta Ophthalmol，2012，90(2)：139-145.
［28］　MELVILLE H，CARPINIELLO M，HOLLIS K，STAFFARONI A，GOLESTANEH N.Stem cells：a new paradigm for disease modeling and developing therapies for age-related macular degeneration［J］.J Transl Med，2013，11(1)：1-9.
［29］　SUGINO IK，SUN Q，WANG J，NUNES CF，CHEEWATRAKKOOLPONG N，RAPISTA A，et al.Comparison of FRPE and human embryonic stem cellderived RPE behavior on aged human Bruch’s membrane［J］.Invest Ophthalmol Vis Sci，2011，52(8)：4979-4997.
［30］　DANG Y，ZHANG C，ZHU Y.Stem cell therapies for age-related macular degeneration：the past，present，and future［J］.Clin Interv Aging，2015，10：255-264.
［31］　CASAROLI-MARANO RP，ZARBIN MA.Cell-based therapy for retinal degenerative disease［J］.Dev Ophthalmol，2014，53：XI-XII.
［32］　SCHWARTZ SD，HUBSCHMAN JP，HEILWELL G，FRANCO-CARDENAS V，PAN CK，OSTRICK RM，et al.Embryonic stem cell trials for macular degeneration：a preliminary report［J］.Lancet，2012，379(9817)：713-720.
［33］　CARR AJ，SMART MJ，RAMSDEN CM，POWNER MB，DA CRUZ L，COFFEY PJ.Development of human embryonic stem cell therapies for age-related macular degeneration［J］.Trends Neurosci，2013，36(7)：385-395.
［34］　PEARSON RA，BARBER AC，RIZZI M，HIPPERT C，XUE T，WEST EL，et al.Restoration of vision after transplantation of photoreceptors［J］.Nature，2012，485(7396)：99-103.
［35］　RICKMAN CB，FARSIU S，TOTH CA，KLINGEBORN M.Dry Age-related macular degeneration：mechanisms，therapeutic targets，and imaging［J］.Invest Ophthalmol Vis Sci，2013，54(14)：68-80.
［36］　LE KN，GIBIANSKY L，GOOD J，DAVANCAZE T，LOYET KM，MORIMOTO A，et al.Population pharmacokinetics and pharmacodynamics of lampalizumab administered intravitreally to patients with geographic atrophy［J］.CPT Pharmacometrics Syst Pharmacol，2015，4(10)：595-604.
［37］　SEDDON JM，YU Y，MILLER EC，REYNOLDS R，TAN PL，GOWRISANKAR S，et al.Rare variants in CFI，C3 and C9 are associated with high risk of advanced age-related macular degeneration［J］.Nat Genet，2013，45(11)：1366-1370.
［38］　WEI CX，SUN A，YU Y，LIU Q，TAN YQ，TACHIBANA I，et al.Challenges in the development of therapy for dry age-related macular degeneration［J］.Adv Exp Med Biol，2016，854：103-109.

相似文献/References:

[1]陈放 徐珊 吕伟红 程宏 张洪泉.糖尿病大鼠视网膜的氧化应激损伤及葛根素对其的干预作用[J].眼科新进展,2012,32(1):000.
[2]解正高 陈放 庄朝荣 王健 朱俊 季河清 王雅坤.银杏叶提取物增强大鼠视网膜光损伤模型抗氧化应激能力[J].眼科新进展,2012,32(1):000.
[3]杨鑫 张凤妍 方梦园 张金嵩 彭广华.PUMA 介导氧化应激诱导的人晶状体上皮细胞凋亡[J].眼科新进展,2012,32(5):000.
[4]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[5]喻小龙 谭钢 刘二华 周寿红.罗格列酮对高糖诱导视网膜神经节细胞损伤的保护作用[J].眼科新进展,2013,33(2):000.
[6]王观峰 李文立 邹秀兰 邹玉平 皮荣标 姚敏.硫辛酸烟酸二联体对丙烯醛损伤ARPE-19细胞的保护作用[J].眼科新进展,2013,33(2):000.
[7]王新 李宝华 张明昌 张向东.表基因修饰参与H2O2介导人晶状体上皮细胞SRA01/04的生长停滞[J].眼科新进展,2013,33(8):000.
[8]薛大喜 张毅 杜玲玲 岳超英 刘平.超氧化物歧化酶与年龄相关性白内障关系的研究[J].眼科新进展,2013,33(8):000.
[9]黄煜 郭海科 孟倩丽.氧化应激机制在眼科疾病研究中的新进展[J].眼科新进展,2012,32(1):000.
[10]谷学静 左中夫.姜黄素对糖尿病早期大鼠视网膜Muller细胞的保护作用[J].眼科新进展,2013,33(3):000.

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81670881）
更新日期/Last Update: 2017-04-26